Table 4 Assessment of mediation of the effect of CAD and ATS on mortality by inflammatory parameters (adjusted analysis).

From: The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis

Outcome

All-cause mortality

Infection-related mortality

Total effect β (95%CI)

Direct effect β (95%CI)

Indirect effect β (95%CI)

Effect mediated by inflammatory parameters % (95%CI)

Total effect β (95%CI)

Direct effect β (95%CI)

Indirect effect β (95%CI)

Effect mediated by inflammatory parameters% (95%CI)

Effect Mediation by CRP

CAD+ AMI-

0.05 (-0.07 to 0.17) (P = 0.439)

0.02 (-0.09 to 0.13) (P = 0.407)

0.03(0.01 to 0.06) (P = 0.047)

66% (P = 0.048)

0.03 (-0.07 to 0.14) (P = 0.559)

0.01 (-0.09 to 0.11) (P = 0.876)

0.02 (0.01 to 0.04) (P = 0.035)

73% (P = 0.035)

CAD+ AMI+

0.13 (0.01 to 0.23) (P = 0.038)

0.09 (-0.02 to 0.21) (P = 0.111)

0.03 (0.01 to 0.06) (P = 0.033)

25% (P = 0.033)

0.07 (-0.03 to 0.18) (P = 0.180)

0.05 (-0.04 to 0.13) (P = 0.297)

0.03 (0.01 to 0.05) (P = 0.033)

36% (P = 0.042)

ATS

0.07 (-0.05 to 0.19) (P = 0.257)

0.07 (-0.04 to 0.18) (P = 0.259)

0.01 (-0.02 to 0.04) (P = 0.814)

6% (0.828)

0.04(-0.07 to 0.15) (P = 0.459)

0.04 (-0.07 to 0.15) (P = 0.494)

0.01 (-0.02 to 0.03) (P = 0.812)

7% (P = 0.829)

Effect Mediation by WBC

CAD+ AMI-

0.03 (-0.05 to 0.11) (P = 0.422)

0.04 (-0.05 to 0.10) (P = 0.531)

0.01 (-0.01 to 0.02) (P = 0.223)

25% (P = 0.226)

0.03 (-0.04 to 0.09) (P = 0.362)

0.03 (-0.04 to 0.09) (P = 0.427)

0.01(-0.01 to 0.02) (P = 0.262)

15% (0.258)

CAD+ AMI+

0.13 (0.04 to 0.22) (P = 0.010)

0.13 (0.03 to 0.22) (P = 0.010)

-0.01 (-0.02 to 0.02) (P = 0.796)

1% (P = 0.796)

0.08 (-0.01 to 0.16) (P = 0.065)

0.08 (-0.01 to 0.16) (P = 0.058)

-0.01 (-0.01 to 0.01) (P = 0.796)

1% (0.789)

ATS

0.20 (0.09 to 0.31) (P < 0.001)

0.20 (0.09 to 0.30) (P < 0.001)

0.01 (-0.02 to 0.02) (P = 0.714)

1% (P = 0.728)

0.07 (-0.02 to 0.16) (P = 0.124)

0.07 (-0.02 to 0.16) (P = 0.128)

0.01 (-0.01 to 0.02) (P = 0.716)

2% (P = 0.736)

Effect Mediation by NL ratio

CAD+ AMI-

0.04 (-0.05 to 0.12) (P = 0.416)

0.05 (-0.04 to 0.12) (P = 0.333)

-0.01 (-0.03 to 0.01) (P = 0.590)

14% (P = 0.581)

0.03 (-0.03 to 0.11) (P = 0.364)

0.04 (-0.04 to 0.11) (P = 0.317)

-0.01 (-0.02 to 0.01) (P = 0.594)

8% (P = 0.586)

CAD+ AMI+

0.12 (0.02 to 0.21) (P = 0.006)

0.11 (0.01 to 0.21) (P = 0.031)

0.01 (-0.02 to 0.03) (P = 0.492)

7% (P = 0.512)

0.07 (-0.01 to 0.15) (P = 0.104)

0.07 (-0.02 to 0.15) (P = 0.131)

0.01 (-0.01 to 0.02) (P = 0.491)

8% (P = 0.517)

ATS

0.19 (0.08 to 0.30) (P = 0.001)

0.18 (0.07 to 0.29) (P = 0.002)

0.01 (-0.02 to 0.04) (P = 0.440)

6% (P = 0.452)

0.06 (-0.03 to 0.16) (P = 0.180)

0.06 (-0.04 to 0.15) (P = 0.234)

0.01 (-0.01 to 0.02) (P = 0.429)

10% (P = 0.459)

  1. ATS: Atherothrombotic stroke, CAD + AMI + : Coronary artery disease with history of Acute myocardial infarction; CAD + AMI-: Coronary artery disease without history of Acute myocardial infarction, B: Regression co-efficient, SE: Standard error.
  2. #Adjusted for age, gender, body mass index (BMI), diabetes mellitus (DM), hypertension (HTN), cancer, chronic kidney disease (stage 3–5), asthma, chronic obstructive pulmonary disease (COPD), liver cirrhosis, transplant status, metformin use, statin use, and calcium channel blocker use.
  3. &Additionally adjusted for ATS.
  4. $Additionally adjusted for CAD.
Back to article page